Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: K 252a derivatives - Bio3 Research/Sienna Biopharmaceuticals

Drug Profile

Research programme: K 252a derivatives - Bio3 Research/Sienna Biopharmaceuticals

Alternative Names: CT 335; CT 336; K252a derivatives

Latest Information Update: 15 Dec 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko
  • Class Antiallergics; Carbazoles
  • Mechanism of Action HMGB1 protein inhibitors; Protein tyrosine kinase inhibitors; TrkA receptor antagonists; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Behcet's syndrome; Coronary artery restenosis; Psoriasis

Most Recent Events

  • 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
  • 14 Apr 2010 Discontinued - Preclinical for Behcet's syndrome in Italy (Parenteral)
  • 14 Apr 2010 Discontinued - Preclinical for Coronary artery restenosis in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top